Del-1 gene therapy - Indevus Pharmaceuticals

Drug Profile

Del-1 gene therapy - Indevus Pharmaceuticals

Latest Information Update: 13 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indevus Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Cardiovascular disorders

Most Recent Events

  • 13 Jul 1999 Del-1 gene therapy - Progenitor is now called Del-1 gene therapy - Interneuron
  • 13 Jul 1999 Discontinued-Preclinical for Cancer in USA (Unknown route)
  • 13 Jul 1999 Discontinued-Preclinical for Cardiovascular disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top